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Natural killer (NK) cells are a very important component of the innate immune response
involved in the lysis of virus infected and tumor cells. Aging has a profound impact in
the frequency, phenotype and function of NK cells. Chronic Myeloid Leukemia (CML) is
caused by the BCR-ABL gene formation encoding aberrant oncoprotein tyrosine kinase.
Treatment with tyrosine kinase inhibitors (TKIs) induces durable deepmolecular response.
The response to treatment and life expectancy is lower in older patients with chronic
phase of CML than in younger patients. In this work we analyse NK cells from TKI-treated
CML patients and healthy controls stratified according to age. We have analyzed the
expression of NK receptors, activation markers, NK cell differentiation in CD56bright and
CD56dim NK cell subsets and the expression of CD107a and IFN-γ in NK cells stimulated
with K562. Whereas significant differences on the phenotype and function of NK cells
were found between middle-aged (35–65 years old) and elderly (older than 65) healthy
individuals, NK cells from TKI-treated CML patients do not show significant differences
related with age in most parameters studied, indicating that age is not a limitation of
the NK cell recovery after treatment with TKI. Our results also revealed differences in the
expression of NK receptors, activation markers and functional assays in NK cells from
TKI-treated CML patients compared with age-matched healthy controls. These results
highlight the relevance of NK cells in TKI-treated patients and the need of an extensive
analysis of the effect of aging on NK cell phenotype and function in these patients in
order to define new NK-cell based strategies directed to control CML progression and
achieve long-term disease remission after TKI cessation.
Keywords: aging, CML, NK receptors, activation markers, differentiation markers, cytokines, NK cell subsets,
tyrosine kinase inhibitors
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INTRODUCTION
Natural Killer cells (NK) are innate lymphoid cells (ILCs)
that represent ∼15% of peripheral blood lymphocytes (PBLs).
NK cells share many features with ILC1 although they are
developmentally distinct (1). NK cells can be classified in
two major subpopulations according to CD56 expression.
CD56bright NK cells are less differentiated subpopulation that
represents <10% of peripheral blood NK cells and have an
immune-modulatory role with high production of cytokines
and chemokines. CD56dim NK cells, a more differentiated
subpopulation that represents about 90% of NK cells, are mainly
cytotoxic and interferon-gamma (IFN-γ) producers after direct
contact with target cells (2, 3). A model of differentiation
from immature CD56bright that leads to more mature CD56dim
NK cells in the periphery has been proposed (4). Another
subpopulation of NK cells, that do not express CD56 but express
other NK receptors, expanded in healthy old and HIV-1 or
hepatitis C infected individuals (5, 6), has been defined. NK cell
function depends on a balance between activating and inhibitory
signals triggered by activating and inhibitory receptors (7).
Chronic Myeloid Leukemia (CML) is an aging-associated
disease (approximately half of cases are diagnosed in people
older than 65) caused by reciprocal translocation between
chromosomes 9 and 22 that give rise to the Philadelphia
chromosome (Ph) and the BCR-ABL gene formation that
encodes an oncoprotein tyrosine kinase with an aberrant activity
in the hematopoietic stem cells (8, 9). Age has been included
as a poor prognostic factor for survival in CML (10, 11). About
half of the patients diagnosed with CML are between 60 and 65
years old (12–14) and the response to disease and life expectancy
is lower in older patients with chronic phase of CML than in
younger patients (15, 16). However, elderly CML patients are
underrepresented in clinical studies having a reduced access to
investigational therapies and median age of CML patients in
cancer registries and patients included in clinical trials differs by
10–20 years (13, 14), supporting the interest to study immune
parameters in elderly CML patients.
Immunosenescence is defined as age-associated dysregulation
and dysfunction of the immune system characterized by impaired
protective immunity and decreased efficacy of vaccines (17–
20). These changes mainly affect the adaptive immune response
(21) although consistent findings reveal that innate immune
response is also affected (22, 23). In addition to age, situations
of chronic activation of the human immune system, such as viral
infections, autoimmune diseases and cancer, are involved in the
development of immunosenescence (24–27).
Age-related alterations in frequency, distribution, phenotype,
and function of NK cell subsets have been described, including an
increased expression of CD57 (considered a marker of ‘memory-
like’ NK) and a decreased expression of Natural Cytotoxicity
Receptors (NCRs) and other NK activating receptors (22, 23, 28–
31), CD69 (32), and CD94/NKG2A, and an increase of killer
Ig-like receptors (KIR) (33–35) in older individuals.
Several studies have also found a decrease in the frequency
and function of NK cells in CML patients at the time of
diagnosis, with a progressive functional deterioration during all
phases of the disease (36–39). It has been described a decreased
expression of NKG2A, NKp30, and NKp46 at the time of
diagnosis and changes in the NKG2C and KIR receptors (40, 41).
Patients with CML also show a decrease in NKG2D expression,
that mediates NK anti-CML response through its ligands
MICA/B, when compared with healthy controls (42). NK cells
from acute myeloid leukemia patients also have a downregulated
expression of activating receptors NKp30 and NKp46 (27, 43–45)
and DNAM-1 (27, 46), likely as a consequence of the interaction
with their ligands in leukemic blasts.
The standard treatment for CML patients is based in the
use of tyrosine kinase inhibitors (TKIs) such as imatinib, and
more potent second-generation nilotinib and dasatinib, that have
improved CML poor prognosis (47, 48). TKIs have a direct effect
inhibiting the BCR-ABL1 kinase activity to induce a durable
deep molecular response, a prelude to successful treatment-free
remission that occurs in∼50% of all CML patients who cease TKI
therapy (48–51). In addition to their direct anti-kinase activity,
TKIs contribute to the restoration of immune cell function
leading to the efficient immunological control of CML (41).
Recent studies show the impact of TKIs on NK cells, finding that
the expression of NK activating receptors is restored to normal
levels compared to their low level at the time of diagnosis (40, 41).
Considering that both aging and CML induce changes in
phenotype and function of NK cells, in this work we have studied
the expression of several markers (CD11b, CD27, CD57, CD69,
HLA-DR, NKG2A, NKG2C, NKG2D, NKp30, NKp44, NKp46,
and NKp80) in NK cell subsets, and CD107a and IFN-γ in K562
stimulated NK cells, from CML patients and healthy controls,
stratified according to age in middle-aged and elderly donors.
MATERIALS AND METHODS
Study Subjects
A total of 80 individuals were included in the study, 38 CML
patients treated with first-line TKIs Imatinib, and 42 healthy
controls, stratified in two groups according to age: middle-aged
(35–65 years) and old-age (over 65 years) (Table 1). All the
participants in the study were CMV-seropositive (Non-reactive
IgM and reactive IgG, data not shown). Controls were excluded
of the study if they had infection at the time of sample collection,
suffered or had suffered cancer or autoimmune diseases, were
under immunosuppressive drugs or calcium channel blockers.
The Ethical Committees of the Faculty of Medicine of the
University of Coimbra and the Coimbra Hospital and University
Centre (Portugal) and the Ethics Committee of the Reina Sofia
University Hospital of Cordoba (Spain) approved this study and
all volunteers agreed and signed informed consent to participate.
Procedures of Sample Collection and
Processing
Peripheral blood samples from all individuals were obtained
in heparinized tubes. Flow cytometry studies were performed
on freshly-obtained cells. After antibody staining, BD FACS
Lysing Solution (BD Biosciences, San Jose, CA, USA) was used
for lysis of red blood cells. Subsequently, cells were washed
and resuspended in Dulbecco’s Phosphate Buffered Saline (PBS)
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TABLE 1 | Demographics characteristics of individuals (n = 80).
Group name No. Sex (male: female) Mean (SD)a pb
Middle age (Control) 19 8:11 51 (7.85) 0.924
Middle age (CML*) 19 12:7 51 (8.97)
OLD (Control) 23 10:13 74 (6.17) 0.814
OLD (CML*) 19 12:7 75 (5.71)
aAverage age (Standard Deviation) of the group.
bp-value for the comparison of means between controls and CML, within the same age
group (t-Student test). *TKI-treated CML patients.
pH 7.4 (Ambion, Austin, TX, USA) for later acquisition on
the cytometer. Cell suspensions were acquired in a BD FACS
Canto II cytometer (BD Biosciences, San Jose, CA, USA).
These procedures were performed according to the manufacturer
protocols.
Flow Cytometric Analysis and Monoclonal
Antibodies
Fresh blood was used for the analysis of the surface receptors
by flow cytometry in different tubes. The following mouse anti-
human conjugated monoclonal antibodies (mAbs) were used:
anti-CD3 V500 (clone UCHT1, BD Horizon), anti-CD14 V500
(clone M5E2, BD Horizon), anti-CD19 V500 (clone HIB19,
BD Horizon), anti-CD3 APC-H7 (clone SK7, BD Biosciences),
anti-CD56 PerCP-Cy5.5 (clone HCD56, BD Pharmingen), anti-
CD11b V450 (clone ICRF44, BD Horizon), anti-CD27 FITC
(clone 0323, Biolegend), anti-CD57 Pacific Blue (clone HNK-
1, Biolegend), anti-CD69 FITC (clone FN50, Biolegend), anti-
HLA-DR V500 (clone G46-6, BD Pharmingen), anti-NKp30
Alexa Fluor 647 (clone P30-15, Biolegend), anti-NKp44 Alexa
Fluor 647 (clone P44-8, Biolegend), anti-NKp46 PE (clone
9E2, Biolegend), anti-NKp80 PE (clone SD12, Biolegend),
anti-NKG2A PE (clone 131411, R&D Systems), anti-NKG2C
APC (clone 134591 R&D Systems), anti-NKG2D APC (clone
1D11, Biolegend). The expression of HLA-DR, NKp30, NKp44,
NKp46, NKp80, NKG2D, (measured as Median Fluorescence
Intensity, MFI) and the expression of CD11b, CD27, CD57,
CD69, NKG2A, and NKG2C (measured as relative frequency)
were determined in the different NK cell subpopulations and
analyzed by multiparametric flow cytometry. The data were
analyzed using FlowJo v10 (Tree Star, Inc.) from PBLs, selecting
singlets. NK cells (CD56+ and CD3−/CD14−/CD19−) were
selected and two subpopulations of NK cells were described,
in relation to their expression of CD56, as CD56bright and
CD56dim (Figure S1A). Isotype matched antibodies, labeled with
the appropriate fluorochromes, were used as negative controls.
Representative histograms for the NK cell markers, and the
isotype and fluorochrome of the antibodies used in the studies,
are shown in Figure S1B.
NK Cell Stimulation With K562,
Degranulation Assay, and IFN-γ Staining
Effector peripheral blood mononuclear cells were isolated from
heparinized blood samples by a standard density gradient
procedure (Ficoll-Paque PLUS, Merck KGaA, Darmstadt,
Germany) and counted to adjust the concentration to 50 ×
106cells/mL. Target cells (K562 cell line) were prepared; viability
determined and counted to adjust the concentration to 1 ×
105cells/mL. Then, effector and target cells were mixed in a
25:1 effector-to-target ratio into 12 × 75mm tubes with anti-
CD107a PE (clone H4A3, BD Pharmingen R©) antibody and
brefeldin A (Merck, 10µg/mL). Tubes were incubated in a
humidified CO2 incubator in the water reservoir at the bottom
for 4 h. At the end of incubation cells were washed and
resuspended in 100 µL of 1xPBS (phosphate-buffered saline)
and the extracellular antibodies were added, anti-CD56 APC
(clone B159, BD Pharmingen R©) and anti-CD3V500 (clone
UCTH1, BD Horizon R©). After 15min of incubation at RT in
the dark, suspensions were treated with Fix and Perm A solution
(Invitrogen R©) for 15min, in the dark at room temperature.
Cells were centrifuged at 453 g for 5min and the supernatant
discarded. Next, cells were incubated with Fix and Perm B
solution (Invitrogen R©) and the intracellular antibody anti-IFN-
γ PE-Cy7 (clone B27, BD Horizon R©) for 20min, in the dark at
room temperature. After centrifugation at 453 g for 5min and
supernatant discarded cells were resuspended in 1x PBS and
acquired in the flow cytometer (BD FACS Canto II).
Statistical Analysis
Shapiro-Wilk test was used for checking the normal distribution
of the data. We used Kruskall-Wallis (non-parametric) test
for multiple comparison and Mann-Whitney U-test (non-
parametric) was used to compare specific groups. All tests were
performed using statistical software package SPSS 18.0 (SPSS
Inc., Chicago, IL, USA). Values p < 0.05 were considered
significant. The results were shown as median with interquartile
range and the graphics were performed using GraphPad Prism
software version 6.0 (GraphPad Software, La Jolla, CA, USA).
RESULTS
Expression of Activating and Inhibitory
Receptors on NK Cells From TKI-Treated
CML Patients
We studied the expression of activating and inhibitory receptors
on CD56dim and CD56bright NK cells in healthy donors
and CML patients, stratified in middle age and old age.
The expression of Natural Killer Group 2 (NKG2) receptors
was measured as the percentage of positive cells or as MFI
measured in the total of cells (Figure 1A). Our results showed a
significant decrease in the expression of the inhibitory receptor
NKG2A on CD56dim NK cells in middle-aged CML patients
compared with middle-aged healthy donors and a decrease in
the percentage of NKG2A+CD56bright NK cells in old CML
patients compared with old healthy donors. Age-associated
changes in the expression of NKG2A were only observed in
healthy donors showing an increase with age in the percentage
of NKG2A+CD56bright NK cells. In contrast, NKG2C receptor
expression was not influenced by CML or age. Regarding the
activating receptor NKG2D, we found a significant decrease in
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FIGURE 1 | Expression of Natural Killer Group 2 (NKG2) receptors on NK cell subpopulations. (A) Representative histograms for each marker are shown (the
non-shaded area represents the control, the shaded area of light gray, the CD56dim cells, the shaded one of gray, the CD56bright cells). The percentage of cells
expressing NKG2C, NKG2A, and NKG2D as (MFI) measured in the total of cells, was determined on the surface of each subset by multiparametric flow cytometry. (B)
Expression of activating receptors (NKG2C and NKG2D) and of inhibitory receptor (NKG2A) on CD56bright and CD56dim NK subsets from healthy individuals and
TKI-treated CML patients, stratified according to age (middle-aged 35–65 years and old >65 years). Number of donors: NKG2C middle-aged healthy n = 19,
middle-aged CML n = 13, old healthy n = 23, and old CML n = 10; NKG2D middle-aged healthy n = 18, middle-aged CML n = 10, old healthy n = 23, and old CML
n = 4; NKG2A middle-aged healthy n = 13, middle-aged CML n = 17, old healthy n = 23, and old CML n = 11. The results, expressed as median with interquartile
range, were considered significant at p < 0.05. P-values were determined comparing middle age with old and healthy with TKI-treated CML patients. *p <0.05;
**p <0.01; ***p <0.001.
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the MFI of NKG2D on CD56bright NK cells in old CML patients
compared with old healthy donors, and a decrease with age in
CML patients (Figure 1B).
We have also studied the expression of NCRs on NK cell
subpopulations. Results were expressed as MFI measured in
the total number of cells (Figure 2A). We have found that the
expression of NKp30 and NKp80 (not a NCR) on CD56bright NK
cells and NKp80 on CD56dim NK cells was lower in old CML
patients compared with old healthy donors. NKp80 expression
on CD56bright cells and NKp46 expression on CD56dim NK
cells were significantly decreased in middle-aged CML patients
compared with middle-aged healthy donors. The analysis of age-
associated changes in the expression of NCRs in CML patients
showed a decrease in NKp30 expression on CD56bright NK cells.
No significant differences associated with age (middle-aged vs.
old age) were observed in healthy donors (Figure 2B).
Expression of Activation Markers of NK
Cells From TKI-Treated CML Patients
In this study, we have analyzed the expression of several
activation markers (HLA-DR, CD69, and NKp44) on the surface
of NK cell subsets in resting conditions. CD56bright NK cells in
elderly CML patients showed a decreased expression of HLA-
DR (measured as MFI) and a reduction in the percentage of
CD69 and NKp44 positive cells compared with elderly healthy
donors. An age-associated increase in the expression of these
three markers was observed on CD56bright NK cells in elderly
healthy donors compared with middle-aged healthy donors. In
contrast, in CML patients a decrease of CD69 expression on
CD56bright NK cells was associated with age (Figure 3A).
Regarding the expression of these activation markers on
the CD56dim NK cell subset, our results showed a decreased
expression of these markers in elderly CML patients, as well
as a decreased expression of CD69 and HLA-DR in middle-
aged CML patients compared with age-matched healthy donors.
Nevertheless, it is interesting to highlight the increase observed
in the percentage of NKp44+ cells in middle-aged CML patients
compared with middle-aged healthy donors. We also found
an age-associated increase in the expression of HLA-DR and
NKp44 in healthy individuals and a decrease of CD69 and
NKp44 expression in CD56dim NK cells from elderly CML
patients compared with CD56dim NK cells from middle-aged
CML patients (Figure 3B).
Analysis of NK Cell Differentiation Markers
on NK Cells From TKI-Treated CML
Patients
The analysis of NK cell subsets in healthy donors showed
a decreased percentage of CD56bright that correlated with an
increased percentage of CD56dim NK cells in elderly donors
compared with middle-aged healthy donors. In contrast, no
statistical significant differences in NK cell subset distribution
was observed in CML patients according to age. Percentage of
total NK cells was not influenced by CML or age (Figure 4A).
The expression of CD57 was increased on CD56dim NK cells
from CML patients compared with age-matched healthy donors.
Moreover, in healthy individuals, CD57 expression on both
CD56bright and CD56dim NK cells increased with age (Figure 4B).
The co-expression of CD11b and CD27 markers was also
analyzed in each NK cell subset (Figure 4C). Whereas, a
high percentage of CD56bright NK cells were CD11b+CD27+,
the majority of CD56dim NK cells from peripheral blood
were CD11b+CD27−. Our results revealed a decrease of
CD11b+CD27+CD56dim NK cells associated with CML in
middle-aged individuals and a decrease of this cell subset related
to age in healthy donors (Figure 4C). Not significant differences
were found in CD56bright NK cells.
CD107a Expression and IFN-γ Production
in NK Cells From TKI-Treated CML Patients
Activated With K562
We analyzed the percentage of NK cells expressing CD107a or
IFN-γ after stimulation with the K562 cell line. Representative
analysis of middle-aged and old controls and TKI-treated
CML patients are shown Figures 5A,C. The results did not
show significant differences on CD107a expression and IFN-γ
production in K562 stimulated NK cells between middle-aged
healthy donors and middle-aged CML patients. NK cells from
healthy elderly donors have higher expression of CD107a or
IFN-γ compared with middle-aged healthy donors. In a similar
way the percentage of NK cells expressing CD107a or IFN-
γ was higher in healthy elderly donors than in TKI-treated
CML old patients. On the contrary no significant age-associated
differences on CD107a expression and IFN-γ production were
observed in K562 stimulated NK cells from CML patients
(Figures 5B,D).
As shown in Figure S2, the comparison of cytokine
production in healthy controls vs. TKI-treated CML patients
shows that the expression of IFN-γ by unstimulated NK cells
is higher in middle-aged TKI-treated CML patients and lower
in elderly patients compared with their age-matched controls,
whereas the expression of IL-10 is higher in TKI-treated CML
patients from both age groups compared with their respective
controls.
DISCUSSION
A decrease in the frequency and function of NK cells in
CML patients at the time of diagnosis has been demonstrated,
with a progressive functional deterioration during disease
progression to advanced and blast crisis phase (36–39, 52).
In addition, NK cells from CML patients at diagnosis
show a reduced expression of activating and inhibitory NK
receptors compared to healthy donors (40, 53). NK cells
play an important role in the control of CML not only
during TKI treatment (40, 41) but also after TKI cessation
(54, 55).
It has been shown that life expectancy is lower in older
than in younger patients with chronic phase of CML and that
aging is a poor prognostic factor for survival and response
to treatment in CML (10, 11, 15, 16). Cumulative evidences
support that aging affects NK cell subsets, phenotype and
Frontiers in Immunology | www.frontiersin.org 5 November 2018 | Volume 9 | Article 2587
Rodrigues-Santos et al. NK Cells in TKI-Treated CML Patients
FIGURE 2 | Expression of Natural Cytotoxicity Receptors (NCRs) on CD56bright and CD56dim NK cells. (A) Representative histograms for NKp30, NKp46, and
NKp80 are shown (the shaded area of light gray, the CD56dim cells, the shaded one of gray, the CD56bright cells). Results were expressed as Median Fluorescence
Intensity (MFI), measured in the total of cells. (B) Expression of activating receptors NKp30, NKp46, and NKp80 on CD56bright and CD56dim NK subsets from healthy
individuals and TKI-treated CML patients, stratified according to age (middle-aged 35–65 years and old >65 years). Number of donors: NKp30 and NKp80
middle-aged healthy n = 19, middle-aged CML n = 11, old healthy n = 23, and old CML n = 9; NKp46 middle-aged healthy n = 19, middle-aged CML n = 16, old
healthy n = 23 and old CML n = 10. The results were expressed as median with interquartile range. P-values were determined comparing middle age with old and
healthy with TKI-treated CML patients and were considered significant at p <0.05. * p < 0.05; **p < 0.01; ***p < 0.001.
function (22, 23, 56), including the expression of activating and
inhibitory NK cell receptors (28–30, 57). The analysis of NK
cells from middle-aged and elderly healthy donors, summarized
in Figure 6A, is in line with previous data on the differences
between NK cells from young and old healthy donors. Thus,
there are significant differences in the frequency of NK cells
subsets with different maturation stages. The percentages of more
immature CD56bright NK cells (2, 3), and CD11b+/CD27+ NK
cells, that represent a minor subset of immunoregulatory NK
cells described as an intermediate differentiation stage (58), are
lower in elderly than in middle-aged healthy donors, whereas
the percentage of mature highly cytotoxic CD56dimCD57+ NK
cells is higher in the elderly (Figure 6A), confirming the age-
associated shaping of NK cell subsets (22, 30). The expression
of NK cell activation markers HLA-DR, CD69, and NKp44
is also higher in NK cells from elderly healthy donors, likely
as a consequence of low grade age-associated inflammation
(inflamm-aging) (59). Inflamm-aging is also consistent with
the observation that NK cells from old healthy donors show
higher expression of CD107a or IFN-γ in response to K562
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FIGURE 3 | Expression of activation markers on CD56bright and CD56dim NK cell subpopulations. Determination of activation markers expression (HLA-DR, CD69,
and NKp44) on the surface of CD56bright and CD56dim NK cells from the different study groups. NK cells were not stimulated. (A) Expression of HLA-DR (measured
as MFI), CD69 and NKp44 (in percentage) on CD56bright NK cells. (B) Expression of HLA-DR (MFI) and percentage of CD69 and NKp44 on CD56dim NK cells.
Number of donors: HLA-DR middle-aged healthy n = 19, middle-aged CML n = 13, old healthy n = 23 and old CML n = 15; CD69 middle-aged healthy n = 19,
middle-aged CML n = 12, old healthy n = 23, and old CML n = 15; NKp44 middle-aged healthy n = 19, middle-aged CML n = 11, old healthy n = 23, and old CML
n = 9. The results, expressed as median with interquartile range, were considered significant at p < 0.05. P-values were determined comparing middle age with old
and healthy with TKI-treated CML patients. *p < 0.05; **p <0.01; ***p <0.001.
stimulation than NK cells from middle-aged donors. The effect
of aging on NK cell cytotoxicity and IFN-γ has been extensively
analyzed in discrepant results have been found among different
groups probably due to different selection age ranges, technical
procedures, and health status of the individuals studied although
it is generally accepted that the total number and cytotoxic
function of NK cell are preserved or increased in healthy aging
compared with young and middle-aged individuals (22, 23,
56).
The study of NK cells in middle-aged TKI-treated CML
patients shows that the percentage of CD56bright NK cells
is similar to the percentage found in heathy middle-aged
individuals, whereas the minor population of CD56dim NK
cells co-expressing CD11b and CD27 is dramatically decreased
(Figure 6B). In addition, CD56dim NK cells from TKI-treated
CML patients have higher expression of CD57, a marker of highly
differentiated NK cells (22, 30), and NKp44 indicating that NK
cells from TKI-treated CML patients are highly differentiated
activated NK cells, as it has been recently suggested (40, 54).
However, there is a lower expression of NKp46, NKG2A,
CD69, and HLA-DR on CD56dim NK cells and of NKp80
on CD56bright NK cells (Figure 6B). The comparison of NK
cells from old TKI-treated CML patients with those from old
healthy individuals shows a lower expression of NK receptors
NKp44, NKp80, CD69, and HLA-DR in both CD56bright and
CD56dim NK cells and also a reduced expression of NKp30,
NKG2D, and NKG2A in CD56bright NK cells (Figure 6C). Thus,
despite the well-established observations that CML patients
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FIGURE 4 | NK cell subsets in healthy and TKI-treated CML individuals stratified by age. (A) Percentage of CD56bright and CD56dim NK cells referred to the total of
CD56+ NK cells and NK cells referred of total Lymphocytes from healthy donors and TKI-treated CML patients. (B) Percentage of NK cells expressing CD57
determined in CD56bright and CD56dim NK cell subsets from both healthy and TKI-treated CML individuals. (C) Percentage of CD11b and CD27 positive cells in
CD56bright and CD56dim NK cell subsets from both healthy and TKI-treated CML individuals. Number of donors: CD56bright, CD56dim, and NK cells, middle-aged
healthy n = 19, middle-aged CML n = 19, old healthy n = 23, and old CML n = 19; CD57 middle-aged healthy n = 19, middle-aged CML n = 19, old healthy n = 23,
and old CML n = 18; CD11b+CD27+ middle-aged healthy n = 19, middle-aged CML n = 16, old healthy n = 23, and old CML n = 10. Graphics show the median
with interquartile range. Kruskal-Wallis test was used for multiple comparisons and the Mann-Whitney U-test for the comparison of specific groups. The differences
were considered significant in a range of p < 0.05. *p < 0.05; **p < 0.01; ***p < 0.001.
have a decreased expression of NK receptors at diagnosis (36–
39), our results confirm that NK cells from TKI-treatment
CML patients can express NK activating receptors (40, 41)
such as NKp30, NKp46, and NKp80, although this expression
is heterogeneous and in some cases their levels are lower
than those found in age-matched healthy controls. NKp30
and NKp46 are NCRs involved in NK cells cytotoxicity after
interaction with their ligands on target cells (60). NKp80, is
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FIGURE 5 | Cytokine expression and degranulation in stimulated NK cells. Analysis of CD107a degranulation assay and IFN-γ expression by Natural killer cells
following stimulation with K562 target cells. (A) Representative dotplots and (B) percentage of CD107a in NK cells from healthy donors and TKI-treated CML patients
according to age and CML. (C) Representative dotplots and (D) IFN-γ expression in NK cells from healthy donors and TKI-treated CML patients according to age and
CML (middle-aged healthy n = 16, middle-aged CML n = 15, old healthy n = 23, and old CML n = 8). Numbers in (A,C) represent the percentage of positive cells
referred to the CD56+ NK cells. The results in (B,D) were shown as median with interquartile range. Values of p < 0.05 were considered significant. P-values were
determined comparing middle age with old and healthy with TKI-treated CML patients. *p < 0.05; ***p < 0.001.
an activating C-type lectin-like receptor expressed on NK cells
that interact with its ligand activation-induced C-type lectin
(AICL) expressed on myeloid cells, including myeloid leukemia
cells (61). It has been suggested that after TKI treatment NK
cells are involved in the control of CML blasts (40, 41), thus
the lower expression of these receptors compared with healthy
controls can be the consequence of the interaction of NK cells
with their ligands expressed on leukemic blasts, as suggested
for NK cells from AML patients (44–46). Downregulation of
NKG2D after its interactions with MICA/B ligand is a well-
defined phenomenon in different tumors (62, 63). However, the
expression of NKG2D is well preserved in all NK cell subsets
from TKI treated CML patients, with the exception of CD56bright
from elderly patients, confirming recent studies showing that
the downregulated expression of NKG2D at the time of CML
diagnosis, is restored to normal levels after TKI treatment (40,
41). The comparison of NK cell response to K562 in healthy
controls vs. TKI-treated CML patients did not show significant
differences on CD107a expression in K562 stimulated NK cells
when middle-aged healthy donors were compared with middle-
aged or old CML patients (Figures 6B,C) supporting previous
findings that TKI treatment is associated with immune system
re-activation and restoration of NK cell immune surveillance
in CML patients (40, 41). On the contrary the observation
that the percentage of NK cells expressing CD107a in TKI-
treated CML old patients was lower than in healthy elderly
donors, together with the lower expression of NK receptors in
old TKI-treated CML patients compared with healthy elderly
healthy donors (Figure 6C), support that the alterations on
NK cells observed in healthy elderly donors likely associated
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FIGURE 6 | Schematic representation of major differences in resting and K562 stimulated NK cells according to age and CML. Circles represent NK cell
subpopulations expressing the indicated membrane markers in CD56bright and CD56dim resting NK cells and the expression of CD107a and IFN-γ in K562 stimulated
NK cells. Red color was used for increased expression and green color for decreased expression of the membrane markers in NK cells from healthy old compared
with healthy middle-aged individuals (A), from CML patients compared with age-matched healthy donors (B,C), or in old CML patients compared with middle-aged
CML patients (D).
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with chronic virus infection, such as CMV, and inflamm-aging
are not observed in old TKI-treated CML patients. The high
variability observed in IFN-γ production by NK cells in response
to K562 in healthy donors and the low response observed in
most CML patients, represent a limitation of the study that
precludes to obtain a conclusion on the significance of cytokine
production in the disease control. The NK cell functional
capacity and cytokine production during TKI-treatment and
after TKI cessation in CML patients requires further analysis to
discriminate a possible role in the long-term elimination of CML
blasts (54, 55).
The analysis of the possible effect of age on NK cells
from TKI-treated CML patients shows a lower expression of
activation markers NKp44 and CD69 in elderly compared
with middle-aged TKI-treated CML patients whereas no
significant differences related with age are found in the
other parameters studied, including CD107a expression and
IFN-γ production in K562 stimulated NK cells from TKI-
treated CML patients (Figure 6D), indicating that age is not
a limitation of the NK cell recovery after treatment with
TKI.
In conclusion, despite the deleterious effect of aging in
CML prognosis, our results showing that activating NK cell
receptors can be expressed both in middle-aged and elderly
TKI-treated CML patients highlight the interest to extensively
analyse the effect of aging on NK cell phenotype and function
in these patients. The possibility of enhancing NK cell activity
by using cytokines and immunomodulating agents open new
perspectives for the design of novel clinical trials aiming effective
long-term treatment-free remission after TKI cessation in CML
patients.
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